Le Lézard
Classified in: Health, Science and technology
Subject: FDA

BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib


BERGEN, Norway, Oct. 22, 2019 /PRNewswire/ --  BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, today announces that the U.S. Food and Drug Administration (FDA) has approved Fast Track Designation for bemcentinib for the treatment of elderly patients with acute myeloid leukaemia (AML) whose disease has relapsed. There are currently no marketed drugs specifically approved for all relapsed AML patients, representing a significant unmet medical need. BerGenBio has ongoing phase 2 trials in this indication and plans to seek regulatory advice from the FDA and European Medicines Agency (EMA) to determine the optimal regulatory path for bemcentinib in relapsed AML.

Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious conditions. Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy. A drug that receives Fast Track designation is eligible for the following:

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "We are thrilled that bemcentinib has been granted Fast Track Designation. Not only does this make us eligible for accelerated approval and priority review, but it serves as an important validation of bemcentinib in this significant unmet medical need we are trying to address. Currently, bemcentinib is in expanded Phase II trials in the U.S. and Europe for the treatment of AML and the Company has recently announced positive interim top line data."

About AXL 

AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In cancer, AXL suppresses the body's immune response to tumours and drives cancer treatment failure across many indications. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.

About bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, as monotherapy and in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy). Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.  

About AML 

Acute myeloid leukemia (AML) is the most common type of aggressive leukemia in adults, which has the lowest survival rate for all types of leukemia. In 2018, it is estimated there will be nearly 20,000 new cases of AML diagnosed in the United States. Many AML patients older than age 60 are unable to tolerate intensive induction chemotherapy treatment.  

About BerGenBio ASA 

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer and leukaemia. A first-in-class functional blocking AXL antibody (BGB149) and an AXL-ADC (ADCT-601) are undergoing phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com 

Contacts 

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh,
Nicholas Brown, Carina Jurs,
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

 

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

https://mb.cision.com/Main/15728/2938369/1127529.pdf

Release

 

SOURCE BerGenBio ASA


These press releases may also interest you

at 21:05
Unlearn.AI, developer of the first machine-learning (ML) platform that creates Digital Twins to populate Intelligent Control Arms in clinical studies, today presented results generated from the company's latest Alzheimer's disease model at the...

at 20:00
The 12-Step fellowship, Nicotine Anonymous (NicA), has grown in 37 years to have over 700 weekly ongoing face-to-face mutual support groups in 32 countries. At meetings members share their experience with a process of recovery from nicotine...

at 17:35
MaaT Pharma announced today that leading hemato-oncological experts presented clinical data on the compassionate use of MaaT Pharma's lead full-ecosystem microbiome restoration biotherapeutic, MaaT013. The data included eight patients that developed...

at 17:35
Magenta Therapeutics , a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its MGTA-145 stem cell mobilization program were presented at...

at 16:05
The Bristol-Myers Squibb-Pfizer Alliance today announced results from retrospective real-world data analyses reporting outcomes on the safety and effectiveness of Eliquis® (apixaban) compared to low molecular weight heparin (LMWH) or warfarin for the...

at 14:30
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Baxter International Inc. between February 21, 2019 and October 23, 2019, inclusive (the "Class Period") of the important January 24, 2020 lead plaintiff...



News published on 22 october 2019 at 08:36 and distributed by: